Vyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955

• Vyome Holdings posted a net loss of $719,683 for the three months ended June 30, 2026, widening from $308,760 a year earlier.
• Revenue fell 46.03% to $26,955, driven by lower product sales and royalty income from Sun Pharma.
• Research and development expense surged more than doubled to $506,723 due to scaling regulatory consulting and CMC preparation for VT-1953.
• General and administrative costs rose 37.49% to $364,891 on higher public-company professional fees, staffing, and stock-based compensation.
• VT-1953 received FDA written feedback on its pre-IND package; plans include a Type C meeting before advancing a pivotal program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088402), on August 12, 2026, and is solely responsible for the information contained therein.